journal
MENU ▼
Read by QxMD icon Read
search

P & T: a Peer-reviewed Journal for Formulary Management

journal
https://www.readbyqxmd.com/read/28674477/research-briefs
#1
(no author information available yet)
No abstract text is available yet for this article.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674476/seeking-solutions-to-the-opioid-crisis
#2
J Stephen McIver
At an event focusing on population-health approaches to the opioid epidemic, discussants agreed that better coordination of care, community involvement in finding solutions, and more consistent use of improved pain-control options are required.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674475/drug-induced-qt-prolongation-and-torsades-de-pointes
#3
Matthew Li, Liz G Ramos
Torsades de pointes (TdP)-an uncommon but life-threatening polymorphic ventricular tachycardia-is almost always drug induced. The authors describe the causes, risk factors, symptoms, diagnosis, and treatment of TdP.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674474/heart-failure-a-class-review-of-pharmacotherapy
#4
Ami Shah, Dimple Gandhi, Sneha Srivastava, Kunal J Shah, Rupal Mansukhani
A recent guideline update for the treatment of heart failure has created the need for a new look at the medication classes and trials related to the disease. The authors focus on pharmacological options available for treating the problem.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674473/cancer-immunotherapy-part-2-efficacy-safety-and-other-clinical-considerations
#5
C Lee Ventola
This article, the second in a series of three, provides an overview of the efficacy and safety of cancer immunotherapies ranging from monoclonal antibodies to vaccines, including additional clinical considerations regarding immune checkpoint blockers.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674472/drug-industry-groups-oppose-fda-quality-metrics-plan-the-agency-wants-to-use-manufacturing-data-to-attack-drug-shortages
#6
Stephen Barlas
Raising their voices in nearly unanimous opposition, pharmaceutical manufacturers and their suppliers have mounted a campaign to dissuade the FDA from launching a voluntary program in 2018 that is aimed at reducing drug shortages.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674471/continuing-the-debate-branko-furst-s-alternative-model-and-the-role-of-the-heart
#7
COMMENT
Rafael Dalmau
No abstract text is available yet for this article.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674470/eluxadoline-viberzi-a-mu-opioid-receptor-agonist-for-the-treatment-of-irritable-bowel-syndrome-with-diarrhea
#8
Fraidy Maltz, Brooke Fidler
Eluxadoline (Viberzi) for the treatment of irritable bowel syndrome with diarrhea.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674469/pharmaceutical-approval-update
#9
Mary Choy
Niraparib (Zejula) for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; ocrelizumab (Ocrevus) for relapsing or primary progressive multiple sclerosis; and dupilumab (Dupixent) for moderate-to-severe atopic dermatitis.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674468/drug-and-device-news
#10
(no author information available yet)
Approvals, new indications, regulatory activities, and more.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674467/significant-change-coming-in-2018-in-tiering-exceptions-policy-for-part-d
#11
Stephen Barlas
A significant change in tiering exceptions policy for Part D is coming in 2018.
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28674466/strengthen-your-resolve-no-unlabeled-containers-anywhere-ever
#12
Matthew Grissinger
Strengthen your resolve: no unlabeled containers anywhere, ever!
July 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579730/research-briefs
#13
(no author information available yet)
No abstract text is available yet for this article.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579729/academy-of-managed-care-pharmacy
#14
John Jesitus, Peter Sonnenreich
Highlights of the AMCP Annual Meeting included marketplace trends, the affordability crisis, and the issues facing value-based contracting.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579728/easl-international-liver-congress-2017
#15
Walter Alexander
The latest in hepatology research was presented at this year's European Association for the Study of the Liver (EASL) International Liver Congress.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579727/immunotherapies-in-late-stage-development-for-patients-with-severe-sle-and-or-lupus-nephritis
#16
Chris Fellner
We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579726/inpatient-antineoplastic-medication-administration-and-associated-drug-costs-institution-of-a-hospital-policy-limiting-inpatient-administration
#17
Alexandra E Foster, David J Reeves
BACKGROUND: Cancer treatment costs are increasing; the global cost of antineoplastic medications rose to $83.7 billion in 2015. As a result, it is imperative for institutions to implement cost-saving strategies and to maximize reimbursement for costly medications such as antineoplastic drugs. OBJECTIVES: Evaluate the necessity and drug costs of administering antineoplastic medications in the inpatient setting and explore savings associated with the 2013 implementation of an institutional policy that defined criteria necessitating inpatient administration of antineoplastic medication...
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579725/cost-savings-from-an-antipsychotic-tablet-splitting-program
#18
Heather Carey, Mark Fondriest
BACKGROUND: Newer atypical antipsychotics such as aripiprazole (Abilify, Otsuka) and lurasidone (Latuda, Sunovion) have favorable safety and efficacy profiles, but their use is limited by high cost. University Hospitals Richmond Medical Center initiated an antipsychotic tablet-splitting program in August 2015 to counter the costs based on the identical pricing structure of aripiprazole and lurasidone doses. METHODS: A retrospective chart review was completed for all patients dispensed aripiprazole or lurasidone oral tablets from May 1, 2015, through December 31, 2015, to evaluate the potential cost-savings for our facility...
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579724/cancer-immunotherapy-part-1-current-strategies-and-agents
#19
C Lee Ventola
This article, the first in a series of three, introduces cancer immunology, cancer immunotherapy strategies, and the classes of anticancer therapeutic agents.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28579723/pimavanserin-nuplazid-a-treatment-for-hallucinations-and-delusions-associated-with-parkinson-s-disease
#20
Martin Paspe Cruz
Pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Parkinson's disease.
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
journal
journal
30579
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"